As I said the other day, Innova antibody tests will be vital following receiving a vaccine to determine long-term efficacy, IOW, how long your body retains antivirus capability.

So a vaccine registry has to be considered in the context of an ecosystem that reports not only nonpersonal data, record keeping but useful AI analytics from follow-up tests that Innova can do and QDX HealthID can record.

Those contracts are won by performance, not PRs, and those discussions are private, not public.